Neurocrine Biosciences (NBIX) says it's initiated Phase IIb clinical trials of NBI-98854, its...

|About: Neurocrine Biosciences, Inc. (NBIX)|By:, SA News Editor

Neurocrine Biosciences (NBIX) says it's initiated Phase IIb clinical trials of NBI-98854, its proprietary Vesicular Mono-Amine Transporter 2 compound for the treatment of severe tardive dyskinesia and underlying schizophrenia or schizoaffective disorder. Topline data on the study is expected in 2Q13.